The assumption seems obvious: if prices are hidden, markets malfunction; reveal them, and competition will discipline costs.
Healthcare policy in the United States has increasingly embraced this intuition. From hospital pricing disclosures mandated by the Centers for Medicare & Medicaid Services to pharmaceutical transparency initiatives proposed across multiple administrations, policymakers have attempted to expose the economic architecture of the healthcare system. The hospital price transparency rule described in regulatory guidance at https://www.cms.gov/hospital-price-transparency reflects this impulse toward visibility. If negotiated rates become public, the theory goes, employers can negotiate more aggressively, patients can comparison-shop, and inefficient providers will feel pressure to lower prices.
Yet the evidence emerging from transparent markets often produces a more unsettling observation. Prices sometimes rise.
Economists have long recognized the mechanism behind this paradox. In markets characterized by limited competition and asymmetric information, secrecy can sustain price dispersion. Different buyers pay different amounts because they lack reliable reference points. Once prices become visible, however, sellers acquire a new kind of knowledge: the prices their competitors successfully command.
Transparency therefore reduces uncertainty for both sides of the market.
In healthcare, where many regional markets resemble oligopolies rather than competitive exchanges, the result can resemble quiet coordination rather than aggressive price competition. Hospitals that previously negotiated disparate reimbursement contracts suddenly discover how much leverage their peers possess. Insurers that once exploited information asymmetry find their bargaining strategies exposed. The new equilibrium does not necessarily converge downward.
Sometimes it converges upward.
This dynamic has appeared in early analyses of hospital price transparency disclosures. Researchers examining negotiated rate files—datasets required under CMS regulations and described through agency documentation at https://www.cms.gov/priorities/key-initiatives/hospital-price-transparency—have found enormous variation in reimbursement for identical procedures across the same metropolitan region. The immediate policy reaction tends to interpret such dispersion as evidence of inefficiency. But dispersion can also represent the residue of competitive negotiation.
Once those numbers circulate publicly, the negotiation environment changes.
Hospitals with comparatively low reimbursement rates suddenly possess evidence that competitors receive higher payments for identical services. Contract renegotiations follow. Insurers, aware that their negotiated discounts have become visible, adjust their strategies accordingly. What began as a transparency initiative evolves into a renegotiation catalyst.
Pharmaceutical pricing displays a similar tension.
Drug markets already operate through a complex layering of price signals: list prices reported as Wholesale Acquisition Cost, net manufacturer revenue reflected in Average Sales Price benchmarks, and acquisition estimates captured in datasets such as the National Average Drug Acquisition Cost survey published by CMS at https://www.medicaid.gov/medicaid/prescription-drugs/pharmacy-pricing/index.html. Transparency policies that highlight one layer of this structure can inadvertently reshape behavior within another.
Consider rebates.
Pharmacy benefit managers negotiate manufacturer rebates partly in exchange for favorable formulary placement. These negotiations historically occurred behind contractual firewalls. When policymakers began scrutinizing rebate structures—through proposals such as the HHS rebate rule described in regulatory materials at https://www.hhs.gov/about/news/2019/01/31/hhs-proposes-rule-to-lower-drug-costs-by-eliminating-kickbacks-to-middlemen.html—the visibility of those arrangements changed the incentives surrounding them.
Manufacturers could respond by increasing list prices while preserving net price flexibility through larger rebates. The nominal price becomes politically visible; the negotiated price remains partially obscured. Transparency therefore moves the distortion rather than eliminating it.
Healthcare price transparency presumes that patients behave like ordinary consumers once information becomes available. Yet the conditions under which most medical decisions occur—clinical urgency, insurance benefit design, fragmented provider networks—rarely resemble traditional retail markets. A patient confronting a diagnosis rarely has the time, or the informational clarity, to interpret machine-readable pricing files published by hospital systems.
Transparency without navigational structure can resemble noise.
This does not render the policy useless. On the contrary, transparency has begun to alter behavior among actors capable of interpreting large pricing datasets. Employers sponsoring self-funded health plans increasingly analyze negotiated rate files to identify pricing outliers within their networks. Data journalists have used these disclosures to investigate regional hospital consolidation. Startups and policy platforms are emerging to translate administrative pricing data into more intelligible signals.
In that sense transparency may function less as a consumer tool than as a research instrument.
Datasets once buried within administrative reporting requirements—hospital negotiated rate files, pharmacy acquisition benchmarks, Medicare reimbursement datasets—are now circulating through a growing ecosystem of analysts, policy researchers, and entrepreneurs. Some platforms examine pharmacy acquisition benchmarks alongside retail price signals to illuminate the distance between acquisition cost and patient payment. The analytical goal is not necessarily to reduce prices immediately but to map the hidden topography of the healthcare market.
Even mapping can produce unintended consequences.
Information reshapes bargaining power. When employers discover large price disparities among hospitals, they may steer patients toward lower-cost facilities through reference pricing. When providers observe those steering mechanisms, they adjust pricing strategies accordingly. The system becomes more dynamic, but not necessarily cheaper.
Transparency therefore exposes a deeper structural truth about healthcare markets.
Prices in healthcare are not merely signals of cost. They are artifacts of negotiation, regulation, and institutional leverage. Revealing those artifacts does not eliminate them. It simply changes who can see them—and how they respond.
The transparency movement has therefore entered an ambiguous phase.
Policy designers expected that sunlight would produce competitive discipline. In some cases it has. In others it has simply redistributed information among sophisticated market participants who already possess substantial negotiating power. The result is a market that is more legible but not necessarily more orderly.
Healthcare economists sometimes describe transparency as a precondition for efficient markets. The experience of recent policy experiments suggests a more complicated interpretation.
Transparency reveals the system. It does not guarantee that the system behaves differently once seen.
